Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells

Oncogene volume 21, pages 2584–2592 (2002)Cite this article

Abstract

Interleukin-6 (IL-6) is a major survival and proliferation factor of human malignant plasma cells and IL-6 dependent myeloma cell lines can be obtained from patients with terminal disease. We show here that mutated diphtheria toxin, a specific inhibitor of heparin-binding epidermal growth factor-like growth factor (HB-EGF), blocked the IL-6-induced growth of two myeloma cell lines (XG-1 and XG-14) and did not significantly affect that of two other cell lines (XG-6 and XG-13). The IL-6 mediated growth of myeloma cells was also inhibited by antibodies to ErbB1, a receptor for HB-EGF. The XG-1 and XG-14 cell lines that are sensitive to HB-EGF inhibitors overexpressed HB-EGF and EGF receptor (ErbB1) genes. They also overexpressed CD9, a tetraspanin that binds to the heparin-binding domain of HB-EGF and is critical for promoting ErbB1 activation by HB-EGF. The XG-6 and XG-13 myeloma cells that were not significantly sensitive to HB-EGF antagonists, poorly expressed HB-EGF, ErbB1 and CD9 genes or proteins. We demonstrated that recombinant HB-EGF supported the long-term growth of myeloma cells, as did IL-6. The myeloma cell growth factor activity of HB-EGF was completely inhited by antibodies to ErbB1, but also by antibodies to gp130 IL-6 transducer or to IL-6. These data indicate that in the XG-1 and XG-14 IL-6-dependent myeloma cell lines, the CD9/HB-EGF/erbB1 and the IL-6/IL-6R/gp130 pathways cooperate synergistically to trigger myeloma cell growth. They suggest that inhibitors of the EGF receptor or HB-EGF may be useful for inducing myeloma cell apoptosis in patients with multiple myeloma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Badache A, Hynes NE . 2001 Cancer Res. 61: 383–391

  • Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B . 1995 Blood 86: 685–691

  • Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, Anderson KC . 1996 Blood 87: 1104–1112

  • Costes V, Magen V, Legouffe E, Durand L, Baldet P, Rossi JF, Klein B, Brochier J . 1999 Hum. Pathol. 30: 1405–1411

  • Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B . 1998 Br. J. Haematol. 103: 1152–1160

  • Davis-Fleischer KM, Besner GE . 1998 Structure and function of heparin-binding EGF-like growth factor (HB-EGF) Front. Biosci. 3: d288–d299

    Article  CAS  Google Scholar 

  • De Vos J, Couderc G, Tarte K, Jourdan M, Requirand G, Delteil MC, Rossi JF, Mechti N, Klein B . 2001 Blood 98: 771–780

  • De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B . 2000 Br. J. Haematol. 109: 823–828

  • Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B . 2000 Br. J. Haematol. 111: 626–634

  • Ferlin-Bezombes M, Jourdan M, Liautard J, Brochier J, Rossi JF, Klein B . 1998 J. Immunol. 161: 2692–2699

  • Gaillard JP, Liautard J, Klein B, Brochier J . 1997 Eur. J. Immunol. 27: 3332–3340

  • Garcia-Sanz R, Orfao A, Gonzalez M, Tabernero MD, Blade J, Moro MJ, Fernandez-Calvo J, Sanz MA, Perez-Simon JA, Rasillo A, Miguel JF . 1999 Blood 93: 1032–1037

  • Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K . 1996 Blood 88: 2250–2258

  • Gu ZJ, Vos JD, Rebouissou C, Jourdan M, Zhang XG, Rossi JF, Wijdenes J, Klein B . 2000 Leukemia 14: 188–197

  • Higashiyama S, Iwamoto R, Goishi K, Raab G, Taniguchi N, Klagsbrun M, Mekada E . 1995 J. Cell. Biol. 128: 929–938

  • Hirata M, Umata T, Takahashi T, Ohnuma M, Miura Y, Iwamoto R, Mekada E . 2001 Biochem. Biophys. Res. Commun. 283: 915–922

  • Iwamoto R, Mekada E . 2000 Cytokine Growth Factor Rev. 11: 335–344

  • Jelinek DF, Witzig TE, Arendt BK . 1997 J. Immunol. 159: 487–496

  • Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, Klein B . 1999 Eur. Cytokine. Netw. 10: 65–70

  • Jourdan M, Vos JD, Mechti N, Klein B . 2000 Cell. Death Differ. 7: 1244–1252

  • Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, Klein B . 1991 J. Immunol. 147: 4402–4407

  • Kaefer M, Vemulapalli S, Freeman MR . 2000 J. Urol. 163: 580–584

  • Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoka H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T . 1988 Nature 332: 83–85

  • Kishimoto T, Akira S, Narazaki M, Taga T . 1995 Blood 86: 1243–1254

  • Klein B, Wijdnes J, Zhang XG, Jourdan M, Boiron JM, Liautard J, Merlin M, Clement C, Morel-Fournier B, Lu ZY, Mannoni P, Sany J, Bataille R . 1991 Blood 78: 1198–1204

  • Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechacyzk M, Bataille R . 1989 Blood 73: 517–526

  • Klein B, Zhang XG, Lu ZY, Bataille R . 1995 Blood 85: 863–872

  • Lokhorst HM, Lamme T, de Smet M, Klein S, de Weger RA, van Oers R, Bloem AC . 1994 Blood 84: 2269–2277

  • Mitamura T, Higashiyama S, Taniguchi N, Klagsbrun M, Mekada E . 1995 J. Biol. Chem. 270: 1015–1019

  • Naglich JG, Metherall JE, Russell DW, Eidels L . 1992 Cell 69: 1051–1061

  • Nakamura K, Mitamura T, Takahashi T, Kobayashi T, Mekada E . 2000 J. Biol. Chem. 275: 18284–18294

  • Portier M, Rajzbaum G, Zhang XG, Attal M, Rusalen C, Wijdenes J, Mannoni P, Maraninchi D, Piechaczyk M, Bataille R, Klein B . 1991 Eur. J. Immunol. 21: 1759–1762

  • Portier M, Zhang XG, Ursule E, Lees D, Jourdan M, Bataille R, Klein B . 1993 Br. J. Haematol. 85: 514–520

  • Qiu Y, Ravi L, Kung HJ . 1998 Nature 393: 83–85

  • Rebouissou C, Wijdenes J, Autissier P, Tarte K, Costes V, Liautard J, Rossi JF, Brochier J, Klein B . 1998 Blood 91: 4727–4737

  • Shimizu S, Yoshioka R, Hirose Y, Susumu S, Tachibana J, Konda S . 1989 J. Exp. Med. 169: 339–344

  • Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Lust JA, Jelinek DF . 1996 Leukemia 10: 866–876

  • Wijdenes J, Heinrich PC, Muller Newen G, Roche C, Gu ZJ, Clement C, Klein B . 1995 Eur. J. Immunol. 25: 3474–3481

  • Yang X, Jia X, Corvalan JR, Wang P, Davis CG . 2001 Crit. Rev. Oncol. Hematol. 38: 17–23

  • Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Boiron JM, Bataille R, Klein B . 1994a Blood 83: 3654–3663

  • Zhang XG, Gu ZJ, Lu ZY, Yasukawa K, Yancopoulos GD, Turner K, Shoyab M, Taga T, Kishimoto T, Bataille R, Klein B . 1994b J. Exp. Med. 179: 1337–1342

Download references

Acknowledgements

This work was supported by a grant from la Ligue Contre le Cancer (Paris, France).

Author information

Authors and Affiliations

  1. INSERM U475 and Unit for Cellular Therapy, CHU Montpellier, 99 Rue Puech Villa, 34197 Montpellier, France

    Yue Dan Wang, John De Vos, Michel Jourdan, Guilhem Couderc, Zhao-Yang Lu, Jean-François Rossi & Bernard Klein

Authors
  1. Yue Dan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John De Vos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michel Jourdan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guilhem Couderc
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhao-Yang Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean-François Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bernard Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernard Klein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, Y., De Vos, J., Jourdan, M. et al. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells. Oncogene 21, 2584–2592 (2002). https://doi.org/10.1038/sj.onc.1205355

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205355

Keywords

This article is cited by

Search

Advanced search

Quick links